The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
The influence of lipophilicity in drug discovery and design
Abstract
INTRODUCTION: The role of lipophilicity in drug discovery and design is a critical one. Lipophilicity is a key physicochemical property that plays a crucial role in determining ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties and the overall suitability of drug candidates. There is increasing evidence to suggest that control of physicochemical properties such as lipophilicity, within a defined optimal range, can improve compound quality and the likelihood of therapeutic success. AREAS COVERED: This review focuses on understanding lipophilicity, techniques used to measure lipophilicity, and summarizes the importance of lipophilicity in drug discovery and development, including a discussion of its impact on individual ADMET parameters as well as its overall influence on the drug discovery and design process, specifically within the past 15 years. EXPERT OPINION: A current review of the literature reveals a continued reliance on the synthesis of novel structures with increased potency, rather than a focus on maintaining optimal physicochemical properties associated with ADMET throughout drug optimization. Particular attention to the optimum region of lipophilicity, as well as monitoring of lipophilic efficiency indices, may contribute significantly to the overall quality of candidate drugs at different stages of discovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420
Structure and function of the blood–brain barrier
Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R., & Begley, D. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.030 · Cited by 5,185
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Prediction of Drug Absorption Using Multivariate Statistics
Egan, W. J., Merz, & Baldwin, J. J. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000292e · Cited by 1,970
Structural Basis of the Drug-binding Specificity of Human Serum Albumin
Ghuman, J., Zunszain, P. A., Petitpas, I., Bhattacharya, A. A., Otagiri, M., & Curry, S. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.07.075 · Cited by 1,941
Cytochrome P450 and Chemical Toxicology
Guengerich, F. P. (2008) · Chemical Research in Toxicology · doi:10.1021/tx700079z · Cited by 1,725
REDFERN, W., CARLSSON, L., DAVIS, A., LYNCH, W., MACKENZIE, I., PALETHORPE, S., SIEGL, P., STRANG, I., SULLIVAN, A., & WALLIS, R. (2003) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00846-5 · Cited by 1,532
Stouffer, S. A. (1950) · Princeton University Press eBooks · Cited by 1,244
Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100008c · Cited by 1,063
Martin, Y. C. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0492002 · Cited by 1,020
Generation of a Set of Simple, Interpretable ADMET Rules of Thumb
Gleeson, M. P. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701122q · Cited by 969
Physiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Quantitative approach to biochemical structure-activity relationships
Hansch, C. (1969) · Accounts of Chemical Research · doi:10.1021/ar50020a002 · Cited by 918
Lipophilicity in drug discovery
Waring, M. J. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441003605098 · Cited by 873
Structure−Brain Exposure Relationships
Hitchcock, S. A., & Pennington, L. D. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060642i · Cited by 698
Mannhold, R., Poda, G. I., Ostermann, C., & Tetko, I. V. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21494 · Cited by 654
The influence of lead discovery strategies on the properties of drug candidates
Keserü, G. M., & Makara, G. M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2796 · Cited by 628
Clark, D. E. (1999) · Journal of Pharmaceutical Sciences · doi:10.1021/js9804011 · Cited by 627
Meanwell, N. A. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200211v · Cited by 620
Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases
Imig, J. D., & Hammock, B. D. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2875 · Cited by 614
Property-Based Design: Optimization of Drug Absorption and Pharmacokinetics
van de Waterbeemd, H., Smith, D. A., Beaumont, K., & Walker, D. K. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm000407e · Cited by 599
Drug binding to human alpha-1-acid glycoprotein in health and disease.
Kremer, J. M., Wilting, J., & Janssen, L. H. (1988) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00015-8 · Cited by 583
Solubility and partitioning I: Solubility of nonelectrolytes in water
Yalkowsky, S. H., & Valvani, S. C. (1980) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600690814 · Cited by 577
A Comparison of Physiochemical Property Profiles of Development and Marketed Oral Drugs
Wenlock, M. C., Austin, R. P., Barton, P., Davis, A. M., & Leeson, P. D. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm021053p · Cited by 546
A general pattern for substrate recognition by P‐glycoprotein
Seelig, A. (1998) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1998.2510252.x · Cited by 527
Clark, D. E. (1999) · Journal of Pharmaceutical Sciences · doi:10.1021/js980402t · Cited by 519
Methods and Principles in Medicinal Chemistry
(2008) · Methods and principles in medicinal chemistry · doi:10.1002/series6138 · Cited by 514
Probing the links between in vitro potency, ADMET and physicochemical parameters
Gleeson, M. P., Hersey, A., Montanari, D., & Overington, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3367 · Cited by 503
Obach, R. S., Lombardo, F., & Waters, N. J. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.020479 · Cited by 462
Lipophilicity and Its Relationship with Passive Drug Permeation
Liu, X., Testa, B., & Fahr, A. (2011) · Pharmaceutical Research · doi:10.1007/s11095-010-0303-7 · Cited by 459
Valkó, K., Bevan, C., & Reynolds, D. (1997) · Analytical Chemistry · doi:10.1021/ac961242d · Cited by 437
Medicinal Chemistry of hERG Optimizations: Highlights and Hang-Ups
Jamieson, C., Moir, E. M., Rankovic, Z., & Wishart, G. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060379l · Cited by 423
Using the Golden Triangle to optimize clearance and oral absorption
Johnson, T. W., Dress, K. R., & Edwards, M. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.08.045 · Cited by 392
What Do Medicinal Chemists Actually Make? A 50-Year Retrospective
Walters, W. P., Green, J., Weiss, J. R., & Murcko, M. A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200504p · Cited by 387
Cavalli, A., Poluzzi, E., De Ponti, F., & Recanatini, M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm0208875 · Cited by 382
Camenisch, G., Alsenz, J., van de Waterbeemd, H., & Folkers, G. (1998) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(97)10019-7 · Cited by 347
Anderson, N., & Borlak, J. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.08.061 · Cited by 346
Wyatt, P. G., Woodhead, A. J., Berdini, V., Boulstridge, J. A., Carr, M. G., Cross, D. M., Davis, D. J., Devine, L. A., Early, T. R., Feltell, R. E., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800382h · Cited by 340
Valko, K., Nunhuck, S., Bevan, C., Abraham, M. H., & Reynolds, D. P. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10494 · Cited by 340
Varma, M. V. S., Obach, R. S., Rotter, C., Miller, H. R., Chang, G., Steyn, S. J., El-Kattan, A., & Troutman, M. D. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901371v · Cited by 331
Bender, A., Scheiber, J., Glick, M., Davies, J. W., Azzaoui, K., Hamon, J., Urban, L., Whitebread, S., & Jenkins, J. L. (2007) · ChemMedChem · doi:10.1002/cmdc.200700026 · Cited by 327
Time-Related Differences in the Physical Property Profiles of Oral Drugs
Leeson, P. D., & Davis, A. M. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049717d · Cited by 326
Waring, M. J. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.03.109 · Cited by 326
Young, R. J., Green, D. V. S., Luscombe, C. N., & Hill, A. P. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.06.001 · Cited by 311
QSAR Model for Drug Human Oral Bioavailability
Yoshida, F., & Topliss, J. G. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm0000564 · Cited by 299
Methods and Principles in Medicinal Chemistry
(2007) · Methods and Principles in Medicinal Chemistry · doi:10.1002/9783527610907.scard · Cited by 298
Summerfield, S. G., Read, K., Begley, D. J., Obradovic, T., Hidalgo, I. J., Coggon, S., Lewis, A. V., Porter, R. A., & Jeffrey, P. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.121525 · Cited by 283
Ryckmans, T., Edwards, M. P., Horne, V. A., Correia, A. M., Owen, D. R., Thompson, L. R., Tran, I., Tutt, M. F., & Young, T. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.05.062 · Cited by 270
Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity
Hill, A. P., & Young, R. J. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.05.016 · Cited by 258
Effect of Altered Plasma Protein Binding on Apparent Volume of Distribution
Øie, S., & Tozer, T. N. (1979) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600680948 · Cited by 256
Hou, T., & Xu, X. (2002) · Journal of Molecular Modeling · doi:10.1007/s00894-002-0101-1 · Cited by 255
Lipophilicity in PK design: methyl, ethyl, futile
van de Waterbeemd, H., Smith, D. A., & Jones, B. C. (2001) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1008192010023 · Cited by 244
Drug-induced phospholipidosis: issues and future directions
Reasor, M. J., Hastings, K. L., & Ulrich, R. G. (2006) · Expert Opinion on Drug Safety · doi:10.1517/14740338.5.4.567 · Cited by 225
Avdeef, A. (1993) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600820214 · Cited by 224
Physicochemical Determinants of Human Renal Clearance
Varma, M. V. S., Feng, B., Obach, R. S., Troutman, M. D., Chupka, J., Miller, H. R., & El-Kattan, A. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900403j · Cited by 213
Lombardo, F., Obach, R. S., Shalaeva, M. Y., & Gao, F. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm0200409 · Cited by 213
Modeling Promiscuity Based on in vitro Safety Pharmacology Profiling Data
Azzaoui, K., Hamon, J., Faller, B., Whitebread, S., Jacoby, E., Bender, A., Jenkins, J. L., & Urban, L. (2007) · ChemMedChem · doi:10.1002/cmdc.200700036 · Cited by 176
Interaction of structurally diverse pesticides with thehuman MDR1 gene product P-glycoprotein
Bain, L. J., & LeBlanc, G. A. (1996) · Toxicology and Applied Pharmacology · doi:10.1016/s0041-008x(96)80035-4 · Cited by 175
Squires, M. S., Feltell, R. E., Wallis, N. G., Lewis, E. J., Smith, D.-M., Cross, D. M., Lyons, J. F., & Thompson, N. T. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0890 · Cited by 171
The road map to oral bioavailability: an industrial perspective
Thomas, V. H., Bhattachar, S., Hitchingham, L., Zocharski, P., Naath, M., Surendran, N., Stoner, C. L., & El-Kattan, A. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.4.591 · Cited by 168
Physicochemical drug properties associated within vivotoxicological outcomes: a review
Price, D. A., Blagg, J., Jones, L. H., Greene, N., & Wager, T. T. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250903042318 · Cited by 167
Impact of Lipophilic Efficiency on Compound Quality
Tarcsay, Á., Nyíri, K., & Keserű, G. M. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201388p · Cited by 164
The influence of the 'organizational factor' on compound quality in drug discovery
Leeson, P. D., & St-Gallay, S. A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3552 · Cited by 162
Prediction of Aqueous Solubility of Organic Compounds by the General Solubility Equation (GSE)
Ran, Y., Jain, N., & Yalkowsky, S. H. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci010287z · Cited by 160
Lombardo, F., Obach, R. S., Shalaeva, M. Y., & Gao, F. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030408h · Cited by 159
A quantitative assessment of hERG liability as a function of lipophilicity
Waring, M. J., & Johnstone, C. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.12.061 · Cited by 159
Adson, A., Burton, P. S., Raub, T. J., Barsuhn, C. L., Audus, K. L., & Ho, N. F. H. (1995) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600841011 · Cited by 157
Peters, J., Schnider, P., Mattei, P., & Kansy, M. (2009) · ChemMedChem · doi:10.1002/cmdc.200800411 · Cited by 156
Tian, S., Li, Y., Wang, J., Zhang, J., & Hou, T. (2011) · Molecular Pharmaceutics · doi:10.1021/mp100444g · Cited by 148
Identification of Inhibitors of Protein Kinase B Using Fragment-Based Lead Discovery
Saxty, G., Woodhead, S. J., Berdini, V., Davies, T. G., Verdonk, M. L., Wyatt, P. G., Boyle, R. G., Barford, D., Downham, R., Garrett, M. D., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070091b · Cited by 141
Plasma Protein Binding Affinity and Its Relationship to Molecular Structure: An In-silico Analysis
Gleeson, M. P. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060981b · Cited by 107
Phospholipidosis as a Function of Basicity, Lipophilicity, and Volume of Distribution of Compounds
Hanumegowda, U., Wenke, G., Regueiro‐Ren, A., Yordanova, R., Corradi, J., & Adams, S. P. (2010) · Chemical Research in Toxicology · doi:10.1021/tx9003825 · Cited by 105
Drug-induced Phospholipidosis -Pathological Aspects and Its Prediction
Nonoyama, T., & Fukuda, R. (2008) · Journal of Toxicologic Pathology · doi:10.1293/tox.21.9 · Cited by 104
Pyrazole NNRTIs 4: Selection of UK-453,061 (lersivirine) as a Development Candidate
Mowbray, C. E., Burt, C., Corbau, R., Gayton, S., Hawes, M., Perros, M., Tran, I., Price, D. A., Quinton, F., Selby, M. D., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.08.080 · Cited by 104
Lewis, D. (2002) · Drug Discovery Today · doi:10.1016/s1359-6446(02)02412-1 · Cited by 93
Design of Selective, ATP-Competitive Inhibitors of Akt
Freeman‐Cook, K. D., Autry, C. L., Borzillo, G. V., Gordon, D., Barbacci-Tobin, E. G., Bernardo, V., Briere, D. M., Clark, T. H., Corbett, M. S., Jakubczak, J. L., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1003842 · Cited by 90
Nassar, A.-E. F., Kamel, A. M., & Clarimont, C. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03297-0 · Cited by 86
Wagner, J. G., & Sedman, A. J. (1973) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01060026 · Cited by 82
Gerebtzoff, G., & Seelig, A. (2006) · Journal of Chemical Information and Modeling · doi:10.1021/ci0600814 · Cited by 82
PHYSICOCHEMICAL AND CELL-BASED APPROACH FOR EARLY SCREENING OF PHOSPHOLIPIDOSIS-INDUCING POTENTIAL
Tomizawa, K., Sugano, K., Yamada, H., et al. (2006) · The Journal of Toxicological Sciences · doi:10.2131/jts.31.315 · Cited by 73
Using an in vitro cytotoxicity assay to aid in compound selection for in vivo safety studies
Greene, N., Aleo, M. D., Louise‐May, S., Price, D. A., & Will, Y. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.06.129 · Cited by 69
Physicochemical properties in pharmacokinetic lead optimization
Krämer, S. D., & Wunderli‐Allenspach, H. (2001) · Il Farmaco · doi:10.1016/s0014-827x(01)01028-x · Cited by 48
Kubinyi, H. (1976) · Journal of Medicinal Chemistry · doi:10.1021/jm00227a004 · Cited by 46
Scherrer, R. A., & Donovan, S. F. (2009) · Analytical Chemistry · doi:10.1021/ac802729k · Cited by 44
Lange, J. H. M., van der Neut, M. A. W., Wals, H. C., Kuil, G. D., Borst, A. J. M., Mulder, A. T., den Hartog, A. P., Zilaout, H., Goutier, W., van Stuivenberg, H. H., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.12.032 · Cited by 32
Lipophilicity assessment of basic drugs (logPo/w determination) by a chromatographic method
Pallicer, J. M., Sales, J., Rosés, M., et al. (2011) · Journal of Chromatography A · doi:10.1016/j.chroma.2011.07.002 · Cited by 30
Pallicer, J. M., Calvet, C., Port, A., et al. (2012) · Journal of Chromatography A · doi:10.1016/j.chroma.2012.03.089 · Cited by 23
The successful quest for oral factor Xa inhibitors; learnings for all of medicinal chemistry?
Young, R. J. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.08.119 · Cited by 21
Chromatographic Hydrophobicity Index (CHI)
Rosés, M., Bosch, E., Ràfols, C., & Fuguet, E. (2012) · Advances in chromatography · doi:10.1201/b11636-9 · Cited by 8
Cited by
Daina, A., Michielin, O., & Zoete, V. (2017) · Scientific Reports · doi:10.1038/srep42717 · Cited by 18,367
The ErbB/HER family of protein-tyrosine kinases and cancer
Roskoski, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.002 · Cited by 1,353
The Current State of Peptide Drug Discovery: Back to the Future?
Henninot, A., Collins, J. C., & Nuss, J. M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00318 · Cited by 1,113
Concepts of Artificial Intelligence for Computer-Assisted Drug Discovery
Yang, X., Wang, Y., Byrne, R., Schneider, G., & Yang, S. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00728 · Cited by 1,022
Daina, A., Michielin, O., & Zoete, V. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500467k · Cited by 974
Metadata
- Authors
- Arnott, J. A., & Planey, S. L.
- Venue
- Expert Opinion on Drug Discovery
- Publisher
- Informa UK Limited
- Published
- 2012-09-19
- Volume
- 7
- Issue
- 10
- Pages
- 863-875
- ISSN
- 1746-0441 (ISSN-L)
- 1746-045X
- OpenAlex
- W2102479939
- Cited by
- 868
- References
- 92
- FWCI
- 15.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.